Last updated: 11/07/2018 19:23:51
A Multi-Centre, Multi-National, Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg BID) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X for a Period of…
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multi-Centre, Multi-National, Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg BID) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X for a Period of…
Trial description: A Multi-Centre, Multi-National, Randomised, Double-Blind, Parallel Group Study to Compare the Efficacy and Tolerability of Salmeterol (50mg BID) Administered by Pressurised Inhaler Propelled by a Mixture of Propellants 11 and 12 or by an Alternative Propellant, GR106642X for a Period of…
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Kraemer B, Dhanak B. Longterm efficacy and tolerability of salmeterol (50mcg BD) administered by pressurised inhaler propelled by propellants 11 and 12 or by an alternative propellant, GR106642X for a period of 12 months in children with reversible airways obstruction. Eur Respir J 1997; 10 (suppl) 25:222s
Medical condition
Asthma
Product
salmeterol
Collaborators
Not applicable
Study date(s)
August 1993 to December 1994
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1994-22-12
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website